Education
About Us
Working with TipRanks
Follow Us
Axsome Therapeutics Inc (AXSM)
NASDAQ:AXSM
Total Valuation
Axsome Therapeutics has a market cap or net worth of $7.34B. The enterprise value is $5.97B.
Market Cap$7.34B
Enterprise Value$5.97B
Share Statistics
Axsome Therapeutics has 50,412,640 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding50,412,640
Owned by Insiders15.70%
Owned by Institutions25.07%
Financial Efficiency
Axsome Therapeutics’s return on equity (ROE) is -5.04 and return on invested capital (ROIC) is -81.71%.
Return on Equity (ROE)-5.04
Return on Assets (ROA)-0.51
Return on Invested Capital (ROIC)-81.71%
Return on Capital Employed (ROCE)-0.83
Revenue Per Employee541.70K
Profits Per Employee-403.39K
Employee Count712
Asset Turnover0.68
Inventory Turnover2.12
Valuation Ratios
The current PE Ratio of Axsome Therapeutics is ―. Axsome Therapeutics’s PEG ratio is -1.03.
PE Ratio―
PS Ratio10.51
PB Ratio71.10
Price to Fair Value71.10
Price to FCF-31.50
Price to Operating Cash Flow-69.97
PEG Ratio-1.03
Income Statement
In the last 12 months, Axsome Therapeutics had revenue of 385.69M and earned -287.22M in profits. Earnings per share was -5.99.
Revenue385.69M
Gross Profit352.39M
Operating Income-280.56M
Pretax Income-287.13M
Net Income-287.22M
EBITDA-272.60M
Earnings Per Share (EPS)-5.99
Cash Flow
In the last 12 months, operating cash flow was -100.95M and capital expenditures -88.00K, giving a free cash flow of -101.04M billion.
Operating Cash Flow-100.95M
Free Cash Flow-101.04M
Free Cash Flow per Share-2.00
Dividends & Yields
Axsome Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.92
52-Week Price Change55.15%
50-Day Moving Average127.51
200-Day Moving Average116.13
Relative Strength Index (RSI)71.14
Average Volume (3m)530.35K
Important Dates
Axsome Therapeutics upcoming earnings date is Mar 2, 2026, Before Open (Confirmed).
Last Earnings DateNov 3, 2025
Next Earnings DateMar 2, 2026
Ex-Dividend Date―
Financial Position
Axsome Therapeutics as a current ratio of 2.11, with Debt / Equity ratio of 293.11%
Current Ratio2.11
Quick Ratio2.04
Debt to Market Cap0.05
Net Debt to EBITDA0.45
Interest Coverage Ratio-42.71
Taxes
In the past 12 months, Axsome Therapeutics has paid 85.00K in taxes.
Income Tax85.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Axsome Therapeutics EV to EBITDA ratio is -14.42, with an EV/FCF ratio of -30.55.
EV to Sales10.19
EV to EBITDA-14.42
EV to Free Cash Flow-30.55
EV to Operating Cash Flow-30.62
Balance Sheet
Axsome Therapeutics has $325.27M in cash and marketable securities with $218.60M in debt, giving a net cash position of $106.68M billion.
Cash & Marketable Securities$325.27M
Total Debt$218.60M
Net Cash$106.68M
Net Cash Per Share$2.12
Tangible Book Value Per Share-$0.04
Margins
Gross margin is 91.86%, with operating margin of -72.74%, and net profit margin of -74.47%.
Gross Margin91.86%
Operating Margin-72.74%
Pretax Margin-74.45%
Net Profit Margin-74.47%
EBITDA Margin-70.68%
EBIT Margin-72.74%
Analyst Forecast
The average price target for Axsome Therapeutics is $175.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$175.25
Price Target Upside19.40% Upside
Analyst ConsensusStrong Buy
Analyst Count15
Revenue Growth Forecast65.83%
EPS Growth Forecast28.50%